Health information to help you understand symptoms. It isn't a diagnosis.
Check symptoms

Research deep dives

When ALS was first described

Last reviewed November 16, 2026. OwieClear editorial team. Waiting for clinician review. Not medical advice. Talk with your doctor about your own care.

ALS was described with remarkable precision in 1869 by a neurologist who had no way of knowing what caused it. His account is still accurate.

Almost everything about the mechanism has been learned in the last thirty years, and the pace has changed considerably in the last fifteen.

Related pages: ALS (amyotrophic lateral sclerosis)

The bottom line

What we know
  • Jean-Martin Charcot described and named ALS in 1869.
  • Lou Gehrig's diagnosis in 1939 made it widely known in the United States.
  • The first ALS gene, SOD1, was identified in 1993.
  • TDP-43 was identified in 2006 and C9orf72 in 2011.
What is still open
  • How much the research funding surge after 2014 will ultimately change outcomes.
  • Whether treatments will emerge for sporadic ALS as they have for SOD1.

The story, step by step

  1. 1. Before Charcot ()
  2. 2. 1869 ()
  3. 3. 1939 ()
  4. 4. 1993 to 2011 ()
  5. 5. 2014 to now ()
What the evidence labels mean
GuidelineAn official recommendation from an expert group after weighing all the evidence.
Review of many studiesCombines the results of many studies (a systematic review or meta-analysis).
Randomized trialPeople were randomly given a treatment or a comparison, the best way to test cause and effect.
Large observational studyFollows many people over time. Shows strong links, but not always cause and effect.
Small or early studyA small study, case series, or first results. Needs to be confirmed.
Lab or animal studyDone in cells or animals. May not apply to people.
Part 1 of 5

Pieces of a picture

Review of many studies

What happens

Parts of the disease were described before anyone put them together.

What the research shows

  • In the 1850s, Francois-Amilcar Aran described a condition of progressive muscular atrophy, affecting lower motor neurons.
  • Guillaume Duchenne described related patterns, including bulbar forms affecting speech and swallowing.
  • These accounts captured the lower motor neuron side without connecting it to the changes in the spinal cord.
  • Anatomical study of the spinal cord after death was the missing tool, and it was becoming available.

Why it matters

The lower motor neuron half of the disease was described first, because it is what you can see in a living patient.

What's still uncertain

  • Attribution of these early descriptions differs between historical accounts.

Read more

Next: 1869

Part 2 of 5

Charcot assembles it

Review of many studies

What happens

Jean-Martin Charcot, at the Salpetriere hospital in Paris, brought the clinical and anatomical halves together.

What the research shows

  • He correlated what he observed in patients during life with what he found in their spinal cords after death.
  • He identified the hardening of the lateral columns, where the corticospinal tracts run, alongside loss of the anterior horn cells.
  • He named it amyotrophic lateral sclerosis, describing both the muscle wasting and the spinal cord change in one term.
  • His description of the clinical picture, including the sparing of sensation and of eye movements, remains accurate.
  • In much of Europe it is still called Charcot's disease.

Why it matters

A description made with a microscope and careful observation, more than 150 years ago, has not needed correcting.

What's still uncertain

  • Charcot's clinicopathological method defined neurology as a discipline and is still how such correlations are made.

Read more

Next: 1939

Part 3 of 5

Lou Gehrig, and public recognition

Review of many studies

What happens

The disease became widely known in the United States through one patient.

What the research shows

  • Lou Gehrig, a baseball player for the New York Yankees known for an extraordinary run of consecutive games, developed weakness during the 1938 and 1939 seasons.
  • He was diagnosed in 1939 and gave a farewell speech at Yankee Stadium that remains widely quoted.
  • He died in 1941, less than two years after diagnosis.
  • The disease became known as Lou Gehrig's disease in the United States, and his case did more for public awareness than any medical publication.
  • The apparent frequency of ALS in athletes has been noticed ever since and studied repeatedly without resolution.

Why it matters

A single patient changing the public profile of a disease is unusual, and in this case it lasted for the better part of a century.

What's still uncertain

  • Whether athletes are genuinely at higher risk remains unresolved.

Read more

Next: 1993 to 2011

Part 4 of 5

The genes arrive

Review of many studies

What happens

The molecular era began with a gene and accelerated from there.

What the research shows

  • In 1993, mutations in SOD1 were identified as a cause of familial ALS. It was the first, and it drove two decades of research and animal models.
  • In 2006, TDP-43 was identified as the protein clumping in the cells of most people with ALS, and also in a form of frontotemporal dementia. That connected two diseases that had seemed separate.
  • In 2011, an expanded repeat in C9orf72 was found to be the most common genetic cause of both ALS and frontotemporal dementia, confirming the link.
  • Riluzole, the first drug shown to extend survival, was approved in 1995 and remained the only one for over twenty years.
  • Each discovery opened a line of drug development, and most of those lines have so far not produced a treatment.

Why it matters

TDP-43 and C9orf72 turned ALS and frontotemporal dementia into a single spectrum, which changed how both are studied.

What's still uncertain

  • Animal models based on SOD1 have been criticized for not representing the majority of human ALS.

Read more

Next: 2014 to now

Part 5 of 5

Money, and the first targeted drug

Review of many studies

What happens

Two developments defined the most recent period.

What the research shows

  • The Ice Bucket Challenge in 2014 raised unprecedented sums for ALS research, and it was widely mocked at the time as frivolous.
  • The funds contributed to several research programmes, including work that helped identify further ALS genes, and the campaign is now generally regarded as having had real scientific impact.
  • Tofersen, approved in the US in 2023 and in Europe in 2024, is the first treatment targeting a specific genetic cause of ALS, for people with SOD1 mutations.
  • Relyvrio was approved and then withdrawn in 2024 after a larger trial failed, a reminder that early positive results do not always hold.
  • Research has shifted toward earlier diagnosis, biomarkers such as neurofilament light chain, and treating people before symptoms appear in families with known genes.

Why it matters

The arc of the last decade is from one drug with a modest effect to a treatment aimed at a specific genetic cause. That is a real change, for a small group so far.

What's still uncertain

  • Whether gene-targeted approaches can be extended to sporadic ALS is the central open question.

Read more

More plain-language reading

See something wrong or unclear on this page? Suggest a correction. OwieClear is for education only and isn't medical advice.